Wednesday, March 29, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

NIAID BAA for Staged HIV Vaccine Development

by Global Biodefense Staff
February 7, 2013

HIV virions budding and releasing from an infected cell (NIAID)The Division of Acquired Immune Deficiency Syndrome (DAIDS) of the National Institute of Allergy and Infectious Diseases (NIAID) is seeking proposals for advanced development and manufacture of preventive HIV-1 vaccines candidates that have shown promise in Non-human primate (NHP) efficacy studies, equivalent preclinical animal models, or early clinical trials.

While industry, government and academia have contributed considerable resources toward development of HIV-1 vaccines over the past 30 years, no fully effective vaccine has emerged. A wide assortment of candidate HIV-1 vaccines have reached Phase I clinical trials but only three vaccine regimens have advanced to efficacy testing. One of these 3 trials has shown modest efficacy in humans and this result, coupled with promising results from nonhuman primate (NHP) studies, has now stimulated the field to continue to test more advanced vaccine candidates in humans.

NIAID will use a staged development approach to allow for the rapid advancement of promising candidates to CGMP manufacturing for subsequent clinical testing. Highlighted areas of interest under this Broad Agency Announcement include:

• Recombinant HIV proteins including HIV envelopes, envelope derivatives, Virus Like Particles (VLPs), as well as formulations of HIV proteins with immune enhancers such as adjuvants and immune modulators.

• POX virus (e.g. Fowlpox, NYVAC, ALVAC, Modified Vaccinia Ankara (MVA) vector-based vaccine candidates.

• DNA vaccines, including DNA delivery device technologies and DNA expressed immune modulators.

• Replication defective adenovirus vectors with low sero-prevelence in the relevant human population.

• Replication competent viral vectors (e.g. Flaviviridae, Adenoviridae, Alphaherpesvirinae Rhabdoviridae)

It is anticipated that 4 to 6 contracts will be awarded beginning on or about July 1, 2014. Each contract will be awarded for up to a two year base period to support Stage I activities and will include options for additional stages based on milestone achievements, scientific priority, program balance, and the availability of funds.

Further details are available under Solicitation Number: BAA-NIAID-DAIDS-NIHAI2012151.

Tags: AdenovirusAnimal ModelsBAAVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC